AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01268384
Drug: Gemcitabine plus Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine 1,250 mg/m2 mixed with 0.9% saline 500 ml i.v. for 10 mg/m2/min on D1 and D8 Capecitabine 950 mg/m2 b.i.d. po from D1 to D14 every 21 days
Trial: NCT01241903
Drug: rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients (n = 54) presenting acute coronary syndrome/non-ST elevation myocardial infarction who present within 8 hours of symptom-onset will be randomized to two groups to receive rosuvastatin (40 mg oral dose) or placebo at the time of presentation, in addition to standard of care (aspirin, clopidogrel, low molecular weight heparin). Blood will be collected at baseline (time of enrollment, immediately prior to drug or placebo), at 6 - 8 hours, at 18 - 24 hours, and at 30 days for analysis of platelet - leukocyte co-aggregate formation, biomarkers of platelet - leukocyte interactions, and biomarkers of myocardial necrosis. Additional samples may be collected just after revascularization, in patients undergoing PCI. The group of patients treated with rosuvastatin will be maintained on rosuvastatin 20 mg daily and the group randomized to placebo will be given rosuvastatin (20 mg oral once daily) within 48 hoursof enrollment and after planned PCI, but before hospital discharge.
Trial: NCT01241903
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: frequency and duration
Trial: NCT01516944
Drug: Oxaliplatin; Capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine,2000 mg/㎡ D1-D14 q3wk and Oxaliplatin,130 mg/㎡ D1 q3wk for two cycle pre-operation, Capecitabine,2000 mg/㎡ D1-D14 q3wk and Oxaliplatin,130 mg/m2 D1 q3wk for six cycles postoperation
Trial: NCT03329690
Drug: DS-8201a
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-8201a is comprised of an antibody component conjoined to a drug component in a lyophilized powder, which is made into solution for intravenous administration.
Trial: NCT03329690
Drug: Physician's Choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Either:~Irinotecan monotherapy (Starting dosage and usage is 150 mg/m2 biweekly, with dose reduction permitted)~Paclitaxel monotherapy (Starting dosage and usage is 80 mg/m2 weekly, with dose reduction permitted)
Trial: NCT02559869
Drug: [18F] GE-180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET Tracer Ligand
Trial: NCT01289769
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline 20 ml( the same volume as dexmedetomidine) giving within 10 minutes.
Trial: NCT00006489
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pill Placebo daily dosing 24 weeks
Trial: NCT02203487
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00712465
Drug: AZD1305
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended Release tablet, repeated administration
Trial: NCT01617057
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg / day for 3 month
Trial: NCT01250470
Drug: Montanide ISA-51/Survivin Peptide Vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given SC
Trial: NCT01565330
Drug: florbetapir F 18
RxNorm normalized name: Florbetapir F 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose IV injection
Trial: NCT01564303
Drug: Acetylcysteine, Phosphodiesterase type 5 inhibitor ,Carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: to evaluate the effect of the above agents on Kidney functioning parameters
Trial: NCT00577512
Drug: DTPACE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Dexamethasone 200 mg Intravenous Infusion Piggy-Back (IVPB) Days 1-7~* Thalidomide 200 mg by mouth (PO) Days 1-7~* Cisplatin 15mg/m2 Days 1-4 (modify for renal insufficiency)~* Adriamycin 15 mg/m2 Days 1-4~* Cyclophosphamide 600 mg/m2 Days 1-4~* Etoposide 60 mg/m2 Days 1-4
Trial: NCT00500292
Drug: FOLFOX regimen=oxaliplatin, fluorouracil, & folinic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion
Trial: NCT03144882
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01625455
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given orally for a total of 7 days.
Trial: NCT02860715
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is the placebo of GX-I7 described above.
Trial: NCT02653651
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An equal volume of saline
Trial: NCT00446147
Drug: Pyridoxine
RxNorm normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mg BID/daily, Per oral
Trial: NCT00446147
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 100mg BID/daily, Per oral
Trial: NCT01644175
Drug: Placebo (for alirocumab)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector (also known as pre-filled pen).
Trial: NCT01644175
Drug: Lipid-Modifying Therapy (LMT)
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
Trial: NCT00864747
Drug: INDERAL® LA 160 mg Capsules, single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B: Active comparator Subjects received Wyeth Pharmaceuticals formulated products non-under fasting conditions
Trial: NCT01747083
Drug: FDC(gemigliptin/metformin HCl sustained release 50/1000mg(25/500mg x 2tablets))
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01705691
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg/m2 IV over 15 minutes on day 1 every 21 days for 4 cycles
Trial: NCT01705691
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m2 IV over 30 minutes on day 1 every 21 days for 4 cycles
Trial: NCT04045678
Drug: Placebo, extended-release microspheres
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients to be enrolled to 70 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week,56 mg in the fourth week and then 70 mg in the next 5 weeks.~Patients to be enrolled to 84 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week,56 mg in the fourth week, 70mg in the fifth week and then 84 mg in the next 5 weeks.
Trial: NCT04220411
Drug: AR100DP1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical ointment
Trial: NCT00181961
Drug: Maca Root
RxNorm normalized name: maca root
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02071524
Drug: Group Colloid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Colloid: cristalloid 1:2 (gelofusine: ringer lactate)
Trial: NCT04407130
Drug: Ivermectin + Doxycycline + Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm I: 200 mcg/kg (12 mg tablet) ivermectin (IVERA) single dose and 200 mg stat doxycycline day-1 followed by 100mg doxycycline 12hrly for 4 day (i.e. day2-day5)~Placebo one tablet D2-5
Trial: NCT04407130
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm III: 3 Placebo tablets D1 followed by 2 tablets D2-5
Trial: NCT00006481
Drug: Biafine cream
RxNorm normalized name: BIAFINE CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02653742
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketorolac 1mg/kg sublingual is administered after induction of general anesthesia.
Trial: NCT02653742
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl 2mg/kg intranasal is administered after induction of general anesthesia
Trial: NCT03738943
Drug: Acetylcholine
RxNorm normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: See arm/group descriptions
Trial: NCT03738943
Drug: Adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: See arm/group descriptions
Trial: NCT03738943
Drug: Vitamin B 6
RxNorm normalized name: vitamin B 6 100 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See arm/group descriptions
Trial: NCT04347382
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empty capsule with 250ml of distilled water
Trial: NCT00748215
Drug: calcium aluminosilicate anti-diarrheal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00962104
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken by mouth, once daily for 10 weeks.
Trial: NCT04056195
Drug: SKI-O-703
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The SKI-O-703 capsules will contain 100 mg of drug substance.
Trial: NCT04056195
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules are filled with microcrystalline cellulose.
Trial: NCT05175066
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets with similar shape and size and color to bisoprolol were given to the patients whom undergone chemotherapy with anthracyclines to compare the effects between two groups.
Trial: NCT00732810
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1250 mg/m\^2 orally twice daily from Day 1 to Day 14 of each 21 day cycle until disease progression.
Trial: NCT00603746
Drug: GW685698X
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW685698X
Trial: NCT01299922
Drug: Mycophenolic Acid + prednison
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mycophenolic Acid + prednison for 106 weeks
Trial: NCT01395329
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gelatin capsule to be taken by mouth once per day for 12 weeks
Trial: NCT00256919
Drug: GW856553
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04702490
Drug: MET409 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MET409 Placebo (50mg)
Trial: NCT01393405
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction period (week 1-16) (Open label):~25 mg MTX sq once weekly + Steroid taper + 1 mg folic acid daily~Maintenance period (week 17-48) (Randomization):~25 mg MTX sq once weekly + 1 mg folic acid daily + 2.4 g mesalamine or Placebo sq once weekly + 1 mg folic acid daily + 2.4 g mesalamine
Trial: NCT04210752
Drug: Treatment 1 (EG-HZ-001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)~Route of Administration: IM injection
Trial: NCT04210752
Drug: Treatment 5
RxNorm normalized name: GNP Cold Sore Treatment 5% Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shingrix~Suspension for injection supplied as a single dose vial of lyophilised VZVgE antigen component to be reconstituted with the accompanying vial of AS01B adjuvant suspension component. After reconstitution, a single dose of ShingrixTM is 0.5 mL.~Route of Administration: IM injection
Trial: NCT01988116
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01524627
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be prescribed to non-abstinent smokers at the same doses as have been demonstrated to be clinically effective for Varenicline: 0.5 mg twice a day for 3 days and then 1mg twice daily for the remainder of the treatment course of 8 weeks.
Trial: NCT00500370
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection (equivalent volume to active dose), twice a day
Trial: NCT01806896
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: - Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.~Dosing for 28 days.
Trial: NCT01806896
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.~* Dosing for 28 days.
Trial: NCT04623333
Drug: TQB2450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB2450 1200mg administered intravenously (IV) on Day 1 of each 21-day cycle.
Trial: NCT02444091
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide intravenous infusions four weeks apart, in total six infusions. First infusion: cyclophosphamide 600mg/m2. Infusions 2 to 6: cyclophosphamide 700 mg/m2 . Follow-up for 12 months.
Trial: NCT00136084
Drug: Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Since limited characters are allowed in this passage, please see detailed Description to know the dosage, dosage form, frequency of administration for the above mentioned drugs
Trial: NCT00136084
Drug: Etoposide, Cytarabine, Gemtuzumab, L-asparaginase, Mercaptopurine, methotrexate, Mitoxantrone, Prednisone, Vincristine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Since limited characters are allowed in this passage, please see detailed Description to know the dosage, dosage form, frequency of administration for the above mentioned drugs
Trial: NCT02531412
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After a major surgery event a time 0, 24h and 48h
Trial: NCT02531412
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After a major surgery event a time 0, 24h and 48h
Trial: NCT04411433
Drug: Favipiravir (3200 mg + 1200 mg) combined with Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin Dosage and method of administration: in a regimen of 1x500 mg (oral) loading dose on day-1 followed by 250 mg maintenance dose (oral daily) on day-2 to day-5 (5 days in total).~Favipiravir Favipiravir Dosage and method of administration: in a regimen of 2x1600 mg (oral) loading dose on day-1 followed by 1200 mg maintenance dose (2x600 mg, 2 times daily) on day-2 to day-5 (5 days in total). The treatment duration may be extended up to 14 days with the evaluation of principle investigator.
Trial: NCT04411433
Drug: Hydroxychloroquine combined with Azithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Hydroxychloroquine combined with Azithromycin Hydroxychloroquine Dosage and method of administration for patients with mild possible or confirmed COVID-19 pneumonia (no severe pneumonia symptoms): in a regimen of 2x400 mg (oral) loading dose on day-1 followed by 400 mg maintenance dose (2x200 mg oral, 2 times daily) on day-2 to day-5 (5 days in total).~Hydroxychloroquine Dosage and method of administration for patients with uncomplicated possible or confirmed COVID-19: in a regimen of 400 mg (2x200 mg oral, 2 times daily) throughout 5 days (5 days in total).~Azithromycin Dosage and method of administration: in a regimen of 1x500 mg (oral) loading dose on day-1 followed by 250 mg maintenance dose (oral daily) on day-2 to day-5 (5 days in total).
Trial: NCT01354132
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets are placed in water or juice in the AM and PM
Trial: NCT00843713
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the patient assigned to the placebo group, subjects will take a matching placebo pill 400mg to be taken by mouth twice daily for 24 weeks in addition to taking their current HIV medication
Trial: NCT01665274
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1,000 mg/m² twice daily, d1-14, q3w
Trial: NCT00997503
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo to match both 10mg and 5mg prasugrel tablets.
Trial: NCT00956930
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75mg fixed dose
Trial: NCT01068444
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 30 mg/d for 6 months
Trial: NCT00929955
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin added to TAU Simvastatin 20mg taken as once daily dose
Trial: NCT00929955
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo added to TAU
Trial: NCT00838266
Drug: mouthrinse (Grape Seed Extract + nicomethanol fluorhydrate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplaque mouthrinse containing active component three times a day, during 1 minute, for 4 days
Trial: NCT00721695
Drug: OMS302
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OMS302 Irrigation Solution
Trial: NCT00721695
Drug: OMS302-PE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OMS302-PE HCI Irrigation Solution
Trial: NCT00721695
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard topical mydriatics and Balanced Salt Solution Irrigation Solution
Trial: NCT01039896
Drug: Period I : SLM0807, Period II : HKB0701 and SLM0807
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01039896
Drug: Period I : HKB0710 and SLM0807, Period II : SLM0807
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03132116
Drug: gentamicin
RxNorm normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After inclusion in the study, patient will be randomized. According to randomization, patient will receive an intra-nodal injection of gentamicin .~As well, azithromycin will be prescribed for all patients for 5 days. Patients will be followed-up each week until week 4 (Day 28).
Trial: NCT03132116
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After inclusion in the study, patient will be randomized. According to randomization, patient will receive an intra-nodal injection of placebo.~As well, azithromycin will be prescribed for all patients for 5 days. Patients will be followed-up each week until week 4 (Day 28).
Trial: NCT03323047
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral acetaminophen (15 mg/kg) 1 hr pre-operatively
Trial: NCT00452725
Drug: MAXOMAT ®, biosynthetic growth hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 posologies according to age (children and adolescents) treatment is planned for a 2 year duration
Trial: NCT03102918
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo over a 6-week treatment period.
Trial: NCT01762943
Drug: Micronized estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All participants will receive micronized estradiol daily for eight weeks. Estradiol will be started at a dose of 4 mg/day and increased progressively up to 10 mg/day.
Trial: NCT01456325
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive onartuzumab matching placebo on Day 1 of every 3-week cycle.
Trial: NCT01819805
Drug: No intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an observational study. Patients taking extended release tramadol hydrochloride 75 mg and acetaminophen 650 mg orally twice daily will be observed.
Trial: NCT00302003
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00302003
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00159588
Drug: Betablockers or other preventive drugs based on primary headache type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Several preventive drugs based on each individual regarding type of original headache type (i.e angiotensin II blockers, betablockers, valproate, tricyclic antidepressants or gabapentin)
Trial: NCT02633956
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once a day (QD) by mouth (PO)
Trial: NCT02227485
Drug: Punica granatum Pleniflora (Golnaar) mouth rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All the patient in intervention group use 10 ml of Golnaar mouth rinse for 2 minutes every night for 2 weeks.
Trial: NCT01529424
Drug: ISIS apoC-III Rx
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose 1
Trial: NCT01529424
Drug: ISIS apoC-III Rx
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose 2
Trial: NCT01529424
Drug: ISIS apoC-III Rx
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose 3
Trial: NCT01529424
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose 1